Thursday 28 November 2024

Mario Klesse

Regional commercial strategy leader in hematologyJohnson & Johnson


Today's issue

Applied Thera tanks, as FDA slaps CRL on govorestat NDA
Pharmaceutical
Applied Thera tanks, as FDA slaps CRL on govorestat NDA
28 November 2024
Biotechnology
Servier’s new bioproduction unit up and running
28 November 2024
Biotechnology
FDA investigates bluebird’s Skysona over cancer risk
28 November 2024
Biotechnology
Acadia signs deal with Saniona for SAN711 rights
28 November 2024
Pharmaceutical
Adragos Pharma acquires Baccinex
28 November 2024
Pharmaceutical
Grifols says takeover talks with Brookfield terminated
28 November 2024
Generics
FDA generic drug science and research priorities for 2025
28 November 2024
Reset all filters
Refine Search

Latest from Mario Klesse

Biotechnology
Toward a functional cure: J&J's ambitions in multiple myeloma
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.   28 November 2024

Company Spotlight

A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.




Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze